JP2007509166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509166A5 JP2007509166A5 JP2006536826A JP2006536826A JP2007509166A5 JP 2007509166 A5 JP2007509166 A5 JP 2007509166A5 JP 2006536826 A JP2006536826 A JP 2006536826A JP 2006536826 A JP2006536826 A JP 2006536826A JP 2007509166 A5 JP2007509166 A5 JP 2007509166A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- antigen
- microbial
- liposaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 53
- 239000000427 antigen Substances 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 230000000813 microbial effect Effects 0.000 claims 17
- 230000002163 immunogen Effects 0.000 claims 16
- 239000013566 allergen Substances 0.000 claims 8
- 230000001580 bacterial effect Effects 0.000 claims 8
- 230000003308 immunostimulating effect Effects 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 8
- 230000002519 immonomodulatory effect Effects 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 230000015788 innate immune response Effects 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 241000894007 species Species 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000033289 adaptive immune response Effects 0.000 claims 3
- 208000030961 allergic reaction Diseases 0.000 claims 3
- 244000005700 microbiome Species 0.000 claims 3
- 244000045947 parasite Species 0.000 claims 3
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 229940065181 bacillus anthracis Drugs 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 235000018185 Betula X alpestris Nutrition 0.000 claims 1
- 235000018212 Betula X uliginosa Nutrition 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 206010061041 Chlamydial infection Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 241000607000 Plesiomonas Species 0.000 claims 1
- 241000605894 Porphyromonas Species 0.000 claims 1
- 101710194807 Protective antigen Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 230000000369 enteropathogenic effect Effects 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51361403P | 2003-10-22 | 2003-10-22 | |
| US60/513,614 | 2003-10-22 | ||
| US55984204P | 2004-04-06 | 2004-04-06 | |
| US60/559,842 | 2004-04-06 | ||
| PCT/US2004/035041 WO2005042017A1 (en) | 2003-10-22 | 2004-10-22 | Compositions and methods for activating innate and allergic immunity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011083368A Division JP2011157380A (ja) | 2003-10-22 | 2011-04-05 | 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509166A JP2007509166A (ja) | 2007-04-12 |
| JP2007509166A5 true JP2007509166A5 (enExample) | 2008-03-13 |
| JP4966661B2 JP4966661B2 (ja) | 2012-07-04 |
Family
ID=34555907
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536826A Expired - Lifetime JP4966661B2 (ja) | 2003-10-22 | 2004-10-22 | 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法 |
| JP2011083368A Pending JP2011157380A (ja) | 2003-10-22 | 2011-04-05 | 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011083368A Pending JP2011157380A (ja) | 2003-10-22 | 2011-04-05 | 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8173140B2 (enExample) |
| EP (2) | EP2174665B1 (enExample) |
| JP (2) | JP4966661B2 (enExample) |
| AT (1) | ATE472336T1 (enExample) |
| CA (1) | CA2543080C (enExample) |
| DE (1) | DE602004027940D1 (enExample) |
| ES (2) | ES2615169T3 (enExample) |
| WO (1) | WO2005042017A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE489968T1 (de) * | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
| US7255867B2 (en) | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
| WO2005042017A1 (en) | 2003-10-22 | 2005-05-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
| SG186686A1 (en) * | 2004-06-25 | 2013-01-30 | Id Biomedical Corp Quebec | Compositions and methods for treating neurological disorders |
| AU2010229835B2 (en) | 2009-03-25 | 2015-01-15 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
| WO2011106525A2 (en) | 2010-02-26 | 2011-09-01 | The Brigham And Women's Hospital, Inc. | Methods of treating cerebral amyloid angiopathy |
| CN103648528A (zh) | 2011-05-13 | 2014-03-19 | 弗利亚生物技术公司 | 番木瓜花叶病毒组合物及其用于刺激先天免疫应答的用途 |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| CN113613665A (zh) * | 2019-03-14 | 2021-11-05 | Om药物公司 | 治疗和/或预防哮喘、哮喘恶化、过敏性哮喘和/或与呼吸系统病症相关的微生物群相关的病症的方法 |
| WO2021222354A2 (en) * | 2020-04-28 | 2021-11-04 | Nova Southeastern University | Compositions including alamandine peptides and methods for treatment of pulmonary disease using alamandine peptides |
| US20220226465A1 (en) | 2021-01-18 | 2022-07-21 | ConserV Bioscience | Coronavirus Immunogenic Compositions, Methods and Uses Thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| DK0815235T3 (da) | 1995-03-13 | 2003-04-22 | Secr Defence | Vacciner mod pest |
| PT854729E (pt) | 1995-09-18 | 2004-08-31 | Us Army Med Res Mat Com Usamrm | Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente |
| WO2001060402A2 (en) | 2000-02-15 | 2001-08-23 | Intellivax International Inc. | Proteosome influenza vaccine |
| CN1549726A (zh) * | 2000-07-31 | 2004-11-24 | 耶鲁大学 | 先天性免疫系统指导的疫苗 |
| ATE489968T1 (de) | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
| EP1379552B2 (en) * | 2001-04-20 | 2014-11-19 | The Institute for Systems Biology | Toll-like receptor 5 ligands and methods of use |
| US8703146B2 (en) * | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| US20040166120A1 (en) * | 2001-06-08 | 2004-08-26 | Thomas Lawrence J. | Vaccination against anthrax |
| US20030026780A1 (en) * | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
| WO2004098636A2 (en) | 2003-05-05 | 2004-11-18 | Id Biomedical Corporation Of Quebec | Vaccinating against infectious diseases using proteosomes |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| WO2005027964A1 (en) * | 2003-09-15 | 2005-03-31 | Id Biomedical Corporation Of Quebec | Measles subunit vaccine |
| WO2005042017A1 (en) * | 2003-10-22 | 2005-05-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
| SG186686A1 (en) | 2004-06-25 | 2013-01-30 | Id Biomedical Corp Quebec | Compositions and methods for treating neurological disorders |
| AU2005319716A1 (en) | 2004-06-30 | 2006-06-29 | Id Biomedical Corporation Of Quebec | Vaccine compositions for treating coronavirus infection |
| CA2722558A1 (en) * | 2008-04-25 | 2009-10-29 | Id Biomedical Corporation Of Quebec | Methods for preparing immunogenic compositions |
-
2004
- 2004-10-22 WO PCT/US2004/035041 patent/WO2005042017A1/en not_active Ceased
- 2004-10-22 US US10/972,062 patent/US8173140B2/en not_active Expired - Lifetime
- 2004-10-22 JP JP2006536826A patent/JP4966661B2/ja not_active Expired - Lifetime
- 2004-10-22 EP EP10001123.8A patent/EP2174665B1/en not_active Expired - Lifetime
- 2004-10-22 ES ES10001123.8T patent/ES2615169T3/es not_active Expired - Lifetime
- 2004-10-22 DE DE602004027940T patent/DE602004027940D1/de not_active Expired - Lifetime
- 2004-10-22 AT AT04796097T patent/ATE472336T1/de not_active IP Right Cessation
- 2004-10-22 ES ES04796097T patent/ES2346441T3/es not_active Expired - Lifetime
- 2004-10-22 EP EP04796097A patent/EP1689433B1/en not_active Expired - Lifetime
- 2004-10-22 CA CA2543080A patent/CA2543080C/en not_active Expired - Lifetime
-
2008
- 2008-04-28 US US12/111,093 patent/US20090324639A1/en not_active Abandoned
-
2011
- 2011-04-05 JP JP2011083368A patent/JP2011157380A/ja active Pending
-
2012
- 2012-04-26 US US13/457,223 patent/US8709447B2/en not_active Expired - Lifetime
-
2014
- 2014-04-28 US US14/263,390 patent/US9433672B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sundararaman et al. | Role of probiotics to combat viral infections with emphasis on COVID-19 | |
| Marinaro et al. | Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4 | |
| Baudner et al. | The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines | |
| JP2007509166A5 (enExample) | ||
| JP2004521925A (ja) | 新規プロテオソーム−リポサッカリドワクチンアジュバント | |
| KR20130112790A (ko) | 백신 조성물 | |
| JP5028627B2 (ja) | ＩｇＡ抗体の選択的産生からＩｇＡ及びＩｇＧ両抗体産生への切換えを可能にする抗原薬物ビークルとこれを用いる経鼻・粘膜ワクチン | |
| CN101745104A (zh) | 含有复合佐剂的结核亚单位疫苗 | |
| Kurashova et al. | Various adjuvants effect on immunogenicity of Puumala virus vaccine | |
| Wang et al. | Potential probiotics for regulation of the gut-lung axis to prevent or alleviate influenza in vulnerable populations | |
| CN1437480A (zh) | 治疗粘膜感染的组合物和方法 | |
| Sloat et al. | Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome–protamine–DNA particles | |
| Knight et al. | Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis | |
| Zhang et al. | Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis | |
| JP2007505836A5 (enExample) | ||
| KR101854904B1 (ko) | 비피막형 헤모필루스 인플루엔자 백신 및 그의 용도 | |
| JPH07106142B2 (ja) | ＩｇＡ誘導能を有するビフィドバクテリウム・ロンガム又はビフィドバクテリウム・ブレーベ | |
| TW201132760A (en) | Pharmaceutical composition and application of detoxified recombinant escherichia coli heat-labile enterotoxin | |
| Xie et al. | Shuffling of pig interleukin-2 gene and its enhancing of immunity in mice to Pasteurella multocida vaccine | |
| Zhang et al. | Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis | |
| WO2009123119A1 (ja) | 合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン | |
| Zhang et al. | CTA1: Purified and display onto gram-positive enhancer matrix (GEM) particles as mucosal adjuvant | |
| CN101687026B (zh) | 突变的大肠杆菌不耐热肠毒素 | |
| Ohmura et al. | Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin | |
| JP2023091085A (ja) | 粘膜アジュバント |